Intellia Therapeutics, Inc.

General ticker "NTLA" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $1.7B (TTM average)

Intellia Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -5.9%.

Estimated limits based on current volatility of 3.4%: low 8.25$, high 8.82$

Factors to consider:

  • Earnings expected soon, date: 2025-05-08 bmo
  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [7.61$, 19.33$]
  • 2025-12-31 to 2026-12-31 estimated range: [5.74$, 14.66$]

Financial Metrics affecting the NTLA estimates:

  • Negative: Non-GAAP EPS, $ of -4.95 <= 0.04
  • Negative: Operating cash flow per share per price, % of -20.48 <= 1.79
  • Negative: negative Net income
  • Negative: negative Operating income
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82
  • Negative: Shareholder equity ratio, % of 73.21 > 63.75

Similar symbols

Short-term NTLA quotes

2025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-0166.577.588.599.5
Price $

Long-term NTLA plot with estimates

1020304050Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−1−0.50
NTLAS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $52.12MM $36.27MM $57.88MM
Operating Expenses $510.29MM $551.57MM $592.14MM
Operating Income $-458.16MM $-515.29MM $-534.26MM
Non-Operating Income $-16.02MM $34.10MM $15.24MM
Interest Expense $8.54MM $0.00MM $0.00MM
R&D Expense $419.98MM $435.07MM $466.31MM
Income(Loss) $-474.19MM $-481.19MM $-519.02MM
Profit(Loss)* $-490.21MM $-481.19MM $-556.85MM
Stockholders Equity $1,235.58MM $1,050.17MM $871.96MM
Inventory $69.34MM $0.00MM $0.00MM
Assets $1,520.11MM $1,300.98MM $1,191.02MM
Operating Cash Flow $-333.29MM $-394.09MM $-348.88MM
Capital expenditure $58.39MM $13.98MM $13.98MM
Investing Cash Flow $160.31MM $-31.35MM $125.57MM
Financing Cash Flow $582.96MM $130.32MM $185.75MM
Earnings Per Share** $-6.37 $-5.42 $-5.63

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.